Chapter 1 Chemotherapy-Induced Peripheral Neuropathy Market Overview
1.1 Chemotherapy-Induced Peripheral Neuropathy Definition
1.2 Global Chemotherapy-Induced Peripheral Neuropathy Market Size Status and Outlook (2017-2031)
1.3 Global Chemotherapy-Induced Peripheral Neuropathy Market Size Comparison by Region (2017-2031)
1.4 Global Chemotherapy-Induced Peripheral Neuropathy Market Size Comparison by Type (2017-2031)
1.5 Global Chemotherapy-Induced Peripheral Neuropathy Market Size Comparison by Application (2017-2031)
1.6 Global Chemotherapy-Induced Peripheral Neuropathy Market Size Comparison by Sales Channel (2017-2031)
1.7 Chemotherapy-Induced Peripheral Neuropathy Market Dynamics
1.7.1 Market Drivers/Opportunities
1.7.2 Market Challenges/Risks
1.7.3 Market News (Mergers/Acquisitions/Expansion)
1.7.4 COVID-19 Impacts
1.7.5 Russia-Ukraine War Impacts
Chapter 2 Chemotherapy-Induced Peripheral Neuropathy Market Segment Analysis by Player
2.1 Global Chemotherapy-Induced Peripheral Neuropathy Sales and Market Share by Player (2020-2022)
2.2 Global Chemotherapy-Induced Peripheral Neuropathy Revenue and Market Share by Player (2020-2022)
2.3 Global Chemotherapy-Induced Peripheral Neuropathy Average Price by Player (2020-2022)
2.4 Players Competition Situation & Trends
2.5 Conclusion of Segment by Player
Chapter 3 Chemotherapy-Induced Peripheral Neuropathy Market Segment Analysis by Type
3.1 Global Chemotherapy-Induced Peripheral Neuropathy Market by Type
3.1.1 Steroids
3.1.2 Antidepressants
3.1.3 Anti-Seizure Medicines
3.1.4 Narcotics
3.1.5 Others
3.2 Global Chemotherapy-Induced Peripheral Neuropathy Sales and Market Share by Type (2017-2022)
3.3 Global Chemotherapy-Induced Peripheral Neuropathy Revenue and Market Share by Type (2017-2022)
3.4 Global Chemotherapy-Induced Peripheral Neuropathy Average Price by Type (2017-2022)
3.5 Leading Players of Chemotherapy-Induced Peripheral Neuropathy by Type in 2022
3.6 Conclusion of Segment by Type
Chapter 4 Chemotherapy-Induced Peripheral Neuropathy Market Segment Analysis by Application
4.1 Global Chemotherapy-Induced Peripheral Neuropathy Market by Application
4.1.1 Hospitals & Clinics
4.1.2 Retail Pharmacy
4.1.3 Online Pharmacy
4.2 Global Chemotherapy-Induced Peripheral Neuropathy Revenue and Market Share by Application (2017-2022)
4.3 Leading Consumers of Chemotherapy-Induced Peripheral Neuropathy by Application in 2022
4.4 Conclusion of Segment by Application
Chapter 5 Chemotherapy-Induced Peripheral Neuropathy Market Segment Analysis by Sales Channel
5.1 Global Chemotherapy-Induced Peripheral Neuropathy Market by Sales Channel
5.1.1 Direct Channel
5.1.2 Distribution Channel
5.2 Global Chemotherapy-Induced Peripheral Neuropathy Revenue and Market Share by Sales Channel (2017-2022)
5.3 Leading Distributors/Dealers of Chemotherapy-Induced Peripheral Neuropathy by Sales Channel in 2022
5.4 Conclusion of Segment by Sales Channel
Chapter 6 Chemotherapy-Induced Peripheral Neuropathy Market Segment Analysis by Region
6.1 Global Chemotherapy-Induced Peripheral Neuropathy Market Size and CAGR by Region (2017-2031)
6.2 Global Chemotherapy-Induced Peripheral Neuropathy Sales and Market Share by Region (2017-2022)
6.3 Global Chemotherapy-Induced Peripheral Neuropathy Revenue and Market Share by Region (2017-2022)
6.4 North America
6.4.1 North America Market by Country
6.4.2 North America Chemotherapy-Induced Peripheral Neuropathy Market Share by Type
6.4.3 North America Chemotherapy-Induced Peripheral Neuropathy Market Share by Application
6.4.4 United States
6.4.5 Canada
6.4.6 Mexico
6.5 Europe
6.5.1 Europe Market by Country
6.5.2 Europe Chemotherapy-Induced Peripheral Neuropathy Market Share by Type
6.5.3 Europe Chemotherapy-Induced Peripheral Neuropathy Market Share by Application
6.5.4 Germany
6.5.5 UK
6.5.6 France
6.5.7 Italy
6.5.8 Russia
6.5.9 Spain
6.6 Asia-Pacific
6.6.1 Asia-Pacific Market by Country
6.6.2 Asia-Pacific Chemotherapy-Induced Peripheral Neuropathy Market Share by Type
6.6.3 Asia-Pacific Chemotherapy-Induced Peripheral Neuropathy Market Share by Application
6.6.4 China
6.6.5 Japan
6.6.6 Korea
6.6.7 India
6.6.8 Southeast Asia
6.6.9 Australia
6.7 South America
6.7.1 South America Market by Country
6.7.2 South America Chemotherapy-Induced Peripheral Neuropathy Market Share by Type
6.7.3 South America Chemotherapy-Induced Peripheral Neuropathy Market Share by Application
6.7.4 Brazil
6.7.5 Argentina
6.7.6 Colombia
6.8 Middle East & Africa
6.8.1 Middle East & Africa Market by Country
6.8.2 Middle East & Africa Chemotherapy-Induced Peripheral Neuropathy Market Share by Type
6.8.3 Middle East & Africa Chemotherapy-Induced Peripheral Neuropathy Market Share by Application
6.8.4 UAE
6.8.5 Saudi Arabia
6.8.6 South Africa
6.9 Conclusion of Segment by Region
Chapter 7 Profile of Leading Chemotherapy-Induced Peripheral Neuropathy Players
7.1 Regenacy Pharmaceuticals
7.1.1 Company Snapshot
7.1.2 Product/Service Offered
7.1.3 Business Performance (Sales, Price, Revenue, Gross Margin and Market Share)
7.2 Asahi Kasei Pharma
7.3 Novaremed
7.4 Makscientific
7.5 Wex Pharmaceuticals
7.6 Sova Pharmaceuticals
7.7 Kineta
7.8 Aptinyx
7.9 Apexian Pharmaceuticals
7.10 Winsantor
Chapter 8 Upstream and Downstream Analysis of Chemotherapy-Induced Peripheral Neuropathy
8.1 Industrial Chain of Chemotherapy-Induced Peripheral Neuropathy
8.2 Upstream of Chemotherapy-Induced Peripheral Neuropathy
8.3 Downstream of Chemotherapy-Induced Peripheral Neuropathy
Chapter 9 Development Trend of Chemotherapy-Induced Peripheral Neuropathy (2023-2031)
9.1 Global Chemotherapy-Induced Peripheral Neuropathy Market Size (Sales and Revenue) Forecast (2023-2031)
9.2 Global Chemotherapy-Induced Peripheral Neuropathy Market Size and CAGR Forecast by Region (2023-2031)
9.3 Global Chemotherapy-Induced Peripheral Neuropathy Market Size and CAGR Forecast by Type (2023-2031)
9.4 Global Chemotherapy-Induced Peripheral Neuropathy Market Size and CAGR Forecast by Application (2023-2031)
9.5 Global Chemotherapy-Induced Peripheral Neuropathy Market Size and CAGR Forecast by Sales Channel (2023-2031)
Chapter 10 Appendix
10.1 Research Methodology
10.2 Data Sources
10.3 Disclaimer
10.4 Analysts Certification
